| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5582031 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 19 Pages |
Abstract
These observations demonstrate that the addition of vorinostat to patients with lenalidomide- and dexamethasone-refractory multiple myeloma was associated with moderate response and was well-tolerated, warranting further assessment in a larger prospective study.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Elizabeth Bilotti, David H. Vesole, Laura McBride, Linda Schmidt, Zhijie Gao, Madiha Gilani, Ann McNeill, Urszula Bednarz, Joshua Richter, Anthony Mato, Thorsten Graef, David S. Siegel,